MedTrace Logo

The Efficacy of Phosphatidylserine-Omega3 in Elderly Subjects With Memory Impairment

NCT00736034 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2010-03-30

Study results available
· View outcomes & findings →

Summary

The primary objective of this trial is to assess the ability of Phosphatidylserine-Omega3 to improve cognitive performance in elderly subjects with memory impairment.

This study is a single-center, open-label 15 weeks duration trial to assess efficacy of Phosphatidylserine-Omega3 in elderly subjects with memory impairment.

Conditions

  • Memory Impairment

Interventions

DIETARY_SUPPLEMENT

Phosphatidylserine-Omega3 (SharpPS™-Gold)

Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks

Sponsors & Collaborators

  • Enzymotec

    lead INDUSTRY

Principal Investigators

  • Veronica Vakhapova, MD · Sourasky Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00736034 on ClinicalTrials.gov